Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Nobilis Health (NYSE: HLTH)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) and Nobilis Health (NYSE: HLTH) with bullish sentiments.

Karyopharm Therapeutics (NASDAQ: KPTI)

In a report released today, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $20. The company’s shares opened today at $7.79.

According to TipRanks.com, Lee is ranked 0 out of 5 stars with an average return of -15.1% and a 28.9% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on Karyopharm Therapeutics is Strong Buy and the average price target is $18, representing a 131.1% upside.

In a report issued on October 31, Jefferies also reiterated a Buy rating on the stock with a $12 price target.
Nobilis Health (NYSE: HLTH)

Canaccord Genuity analyst Neil Maruoka reiterated a Buy rating on Nobilis Health (NYSE: HLTH) today and set a price target of $4.50. The company’s shares opened today at $2.40.

According to TipRanks.com, Maruoka is ranked 0 out of 5 stars with an average return of -42.9% and a 12.5% success rate. Maruoka covers the Healthcare sector, focusing on stocks such as Merus Labs International, Cardiome Pharma Corp., and Concordia Healthcare.

Nobilis Health has an analyst consensus of Moderate Buy.